YU6401A - Primena eletriptana za izradu leka za prevenciju učestanog javljanja migrene - Google Patents

Primena eletriptana za izradu leka za prevenciju učestanog javljanja migrene

Info

Publication number
YU6401A
YU6401A YU6401A YU6401A YU6401A YU 6401 A YU6401 A YU 6401A YU 6401 A YU6401 A YU 6401A YU 6401 A YU6401 A YU 6401A YU 6401 A YU6401 A YU 6401A
Authority
YU
Yugoslavia
Prior art keywords
eletryptane
medicine
prevention
production
application
Prior art date
Application number
YU6401A
Other languages
English (en)
Inventor
Neville Colin Jackson
Stephen Uden
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to YU20303A priority Critical patent/YU20303A/sh
Publication of YU6401A publication Critical patent/YU6401A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pronalazak se odnosi na primenu eletriptana, ili neke njegove farmaceutski prihvatljive soli iil kompozicije, na proizvodnju medikamenta za sprečavanje ponovnog javljanja migrene i na primenu jednog agonista 5-HT18/1D receptora, ili neke njegove farmaceutski prihvatljive soli ili kompozicije, za proizvodnju farmaceutske kompozicije sa dvostrukim, zadržanim, odloženim, konrolisanim ili pulsirajućim ispuštanjem za sprečavanje ponovnog javljanja migrene.
YU6401A 1998-07-30 1999-06-14 Primena eletriptana za izradu leka za prevenciju učestanog javljanja migrene YU6401A (sh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
YU20303A YU20303A (sh) 1998-07-30 1999-06-14 Farmaceutski preparat za prevenciju učestanog javljanja migrene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9816556.6A GB9816556D0 (en) 1998-07-30 1998-07-30 Therapy

Publications (1)

Publication Number Publication Date
YU6401A true YU6401A (sh) 2004-03-12

Family

ID=10836395

Family Applications (2)

Application Number Title Priority Date Filing Date
YU20303A YU20303A (sh) 1998-07-30 1999-06-14 Farmaceutski preparat za prevenciju učestanog javljanja migrene
YU6401A YU6401A (sh) 1998-07-30 1999-06-14 Primena eletriptana za izradu leka za prevenciju učestanog javljanja migrene

Family Applications Before (1)

Application Number Title Priority Date Filing Date
YU20303A YU20303A (sh) 1998-07-30 1999-06-14 Farmaceutski preparat za prevenciju učestanog javljanja migrene

Country Status (35)

Country Link
EP (3) EP1435237A1 (sh)
JP (1) JP3824863B2 (sh)
KR (2) KR100441732B1 (sh)
CN (2) CN1522697A (sh)
AP (1) AP1402A (sh)
AT (1) ATE261304T1 (sh)
AU (1) AU3952199A (sh)
BG (1) BG65309B1 (sh)
BR (1) BR9912588A (sh)
CA (1) CA2338901C (sh)
CZ (1) CZ2001357A3 (sh)
DE (1) DE69915486T2 (sh)
DK (1) DK1100499T3 (sh)
EA (2) EA004036B1 (sh)
EE (1) EE04703B1 (sh)
ES (1) ES2214027T3 (sh)
GB (1) GB9816556D0 (sh)
GE (2) GEP20043157B (sh)
HR (1) HRP20010079A2 (sh)
HU (1) HUP0103424A3 (sh)
ID (1) ID26996A (sh)
IL (1) IL140169A0 (sh)
IS (1) IS2253B (sh)
NO (1) NO20010489L (sh)
NZ (2) NZ508736A (sh)
OA (1) OA11576A (sh)
PL (1) PL194611B1 (sh)
PT (1) PT1100499E (sh)
SG (1) SG125910A1 (sh)
SK (1) SK1182001A3 (sh)
TR (1) TR200100314T2 (sh)
TW (2) TW537893B (sh)
UA (1) UA76399C2 (sh)
WO (1) WO2000006161A1 (sh)
YU (2) YU20303A (sh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
ES2380827T3 (es) * 2002-12-26 2012-05-18 Pozen, Inc. Formas de dosificación con múltiples capas que contienen naproxeno y triptanes
BRPI0409127A (pt) 2003-04-11 2006-03-28 Pfizer combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
CA2765866C (en) 2008-06-20 2016-06-21 Alphapharm Pty Ltd Single phase pharmaceutical composition of a 5-ht1 inhibitor and an nsaid
EP2490669B1 (en) * 2009-10-23 2017-01-11 Fortuderm Ltd. Triptans for the treatment of psoriasis
PT2838517T (pt) * 2012-04-18 2018-01-04 Contera Pharma Aps Formulação farmacêutica disponível sob forma oral adequada para a melhoria da gestão dos distúrbios da mobilidade
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法
CN104523709A (zh) * 2014-12-22 2015-04-22 青岛正大海尔制药有限公司 一种含有琥珀酸夫罗曲坦的复方缓释制剂
CA3030089C (en) 2016-07-11 2024-04-23 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2091562C (en) * 1990-10-15 2001-03-27 John Eugene Macor Indole derivatives useful in psychotherapeutics
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
CA2259418A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
SK284462B6 (sk) * 1997-07-03 2005-04-01 Pfizer Inc. Vodná farmaceutická kompozícia obsahujúca eletriptan hemisulfát a jej použitie
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape

Also Published As

Publication number Publication date
IS2253B (is) 2007-06-15
CN1155379C (zh) 2004-06-30
EP1435237A1 (en) 2004-07-07
TW537893B (en) 2003-06-21
AP2001002056A0 (en) 2001-03-31
ATE261304T1 (de) 2004-03-15
KR100441732B1 (ko) 2004-07-27
JP2002521446A (ja) 2002-07-16
EP1100499A1 (en) 2001-05-23
PL345803A1 (en) 2002-01-02
TR200100314T2 (tr) 2001-06-21
NO20010489L (no) 2001-03-26
CA2338901A1 (en) 2000-02-10
AP1402A (en) 2005-04-29
YU20303A (sh) 2006-08-17
PT1100499E (pt) 2004-06-30
EA004036B1 (ru) 2003-12-25
ES2214027T3 (es) 2004-09-01
KR20010079582A (ko) 2001-08-22
GEP20063719B (en) 2006-01-10
AU3952199A (en) 2000-02-21
UA76399C2 (en) 2006-08-15
WO2000006161A1 (en) 2000-02-10
GEP20043157B (en) 2004-01-26
CN1522697A (zh) 2004-08-25
CA2338901C (en) 2008-02-19
NO20010489D0 (no) 2001-01-29
PL194611B1 (pl) 2007-06-29
ID26996A (id) 2001-02-22
BG105277A (en) 2001-11-30
BG65309B1 (bg) 2008-01-31
EA200100089A1 (ru) 2001-08-27
OA11576A (en) 2004-07-01
EE200100061A (et) 2002-06-17
IS5771A (is) 2000-12-15
BR9912588A (pt) 2001-05-02
TW200300674A (en) 2003-06-16
CN1309560A (zh) 2001-08-22
DK1100499T3 (da) 2004-06-14
GB9816556D0 (en) 1998-09-30
HUP0103424A3 (en) 2003-05-28
KR20030078876A (ko) 2003-10-08
JP3824863B2 (ja) 2006-09-20
SK1182001A3 (en) 2001-10-08
TWI248362B (en) 2006-02-01
EP1100499B1 (en) 2004-03-10
HK1038198A1 (en) 2002-03-08
CZ2001357A3 (cs) 2001-10-17
DE69915486D1 (de) 2004-04-15
NZ527625A (en) 2005-01-28
IL140169A0 (en) 2002-02-10
SG125910A1 (en) 2006-10-30
DE69915486T2 (de) 2005-03-03
EE04703B1 (et) 2006-10-16
EP1466601A2 (en) 2004-10-13
EP1466601A3 (en) 2005-04-13
EA200201149A1 (ru) 2003-02-27
HRP20010079A2 (en) 2002-02-28
NZ508736A (en) 2003-09-26
HUP0103424A2 (hu) 2002-02-28

Similar Documents

Publication Publication Date Title
DE69620606D1 (de) Feste oral anzuwendende arzeneiform
IS1892B (is) Nýjar samsetningar virkra efna sem innihalda klópidógrel og andþrombín
YU48600A (sh) Celekoksibne smese
BRPI0412557A (pt) forma de dosagem farmacêutica de eventos cardiovasculares
AU1729397A (en) Process to prepare soluble delivery systems using volatile salts
MXPA02006151A (es) Composiciones de liberacion dual de un inhibidor de ciclooxigenasa-2.
MY135852A (en) Pharmaceutical products
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
BR0014383A (pt) Composições de liberação controlada compreendendo nimesulida
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
ES2195638T3 (es) Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida.
AR012247A1 (es) Composiciones farmaceuticas y su uso para la preparacion de medicamentos destinados a prevenir y tratar las enfermedades tromboembolicas arteriales
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
IS2369B (is) Ný blanda 5-HT4 gerandefna eða mótlyfja til inntöku um munn
BR9912588A (pt) Prevenção de recorrência de enxaqueca
MA27102A1 (fr) Composition pharmaceutique orodispersible d'ivabradine
MA27099A1 (fr) Composition pharmaceutique orodispersible de perindopril
BR0116558A (pt) Composição farmacêutica em comprimido, base livre de amilodipina, método de tratamento ou prevenção de hipertensão, angina ou congestão cardìaca, processo, processo para purificação de base livre de amlodipina e população base livre de amlodipina em partìculas
BR0108958A (pt) Sistema de liberação controlada, administrado oralmente, para administração diária de ciprofloxacina
MXPA05005893A (es) Composicion farmaceutica de 1-(3-hidroxi -4-metoxifenil) -4-metil-5 -etil-7, 8-dimetoxi- 5h-2, 3-benzodiazepina y usos de la misma.
MXPA01011842A (es) Composiciones farmaceuticas para la administracion oral de floroglucinol y preparacion de las mismas.
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
HRP20050055B1 (hr) Mikrokapsule za odloženo i kontrolirano oslobađanje perindoprila
MY138799A (en) Orodispersible pharmaceutical composition of an antithrombotic compound
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.